Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price increased by equities research analysts at Morgan Stanley from $275.00 to $284.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective suggests a potential upside of 10.74% from the stock’s previous close.

ALNY has been the topic of a number of other reports. TD Cowen upped their price target on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Sanford C. Bernstein cut their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Canaccord Genuity Group boosted their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Needham & Company LLC reiterated a “buy” rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday. Finally, Scotiabank increased their price target on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $299.43.

Alnylam Pharmaceuticals Trading Down 3.2 %

Shares of NASDAQ ALNY opened at $256.45 on Friday. The business has a fifty day simple moving average of $254.03 and a 200-day simple moving average of $263.35. The company has a market cap of $33.08 billion, a price-to-earnings ratio of -97.88 and a beta of 0.35. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Sell-side analysts predict that Alnylam Pharmaceuticals will post -2.24 EPS for the current year.

Insider Buying and Selling

In other news, CEO Yvonne Greenstreet sold 5,219 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the completion of the sale, the chief executive officer now owns 78,880 shares of the company’s stock, valued at approximately $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Tolga Tanguler sold 1,469 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the transaction, the executive vice president now directly owns 13,191 shares in the company, valued at $3,310,677.18. The trade was a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 73,964 shares of company stock worth $20,622,925 in the last quarter. 1.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Creative Planning raised its stake in shares of Alnylam Pharmaceuticals by 24.6% during the third quarter. Creative Planning now owns 10,012 shares of the biopharmaceutical company’s stock worth $2,754,000 after buying an additional 1,978 shares during the last quarter. Swedbank AB grew its position in shares of Alnylam Pharmaceuticals by 160.3% in the 3rd quarter. Swedbank AB now owns 53,729 shares of the biopharmaceutical company’s stock valued at $14,777,000 after purchasing an additional 33,090 shares during the period. Bleakley Financial Group LLC raised its stake in shares of Alnylam Pharmaceuticals by 24.7% in the 3rd quarter. Bleakley Financial Group LLC now owns 2,215 shares of the biopharmaceutical company’s stock valued at $609,000 after purchasing an additional 439 shares during the period. Blue Trust Inc. lifted its stake in Alnylam Pharmaceuticals by 431.0% in the 3rd quarter. Blue Trust Inc. now owns 462 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 375 shares in the last quarter. Finally, Friedenthal Financial acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $51,000. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.